<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114566</url>
  </required_header>
  <id_info>
    <org_study_id>17-211</org_study_id>
    <nct_id>NCT03114566</nct_id>
  </id_info>
  <brief_title>Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors</brief_title>
  <official_title>Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer&#xD;
      donors in order to create Good Manufacturing Practice grade banks of virus-specific and&#xD;
      tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for&#xD;
      therapeutic use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Actual">February 2, 2021</completion_date>
  <primary_completion_date type="Actual">February 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Generation of T-cells</measure>
    <time_frame>1 year</time_frame>
    <description>Blood and/or white cell donations will be used for the generation of the T-cells to be used for adoptive immunotherapy.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Consenting healthy donor</arm_group_label>
    <description>Transplant and healthy HLA typed donors</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <description>Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.</description>
    <arm_group_label>Consenting healthy donor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Transplant donors and healthy HLA typed volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Donors must satisfy standards including those set forth by FACT (Foundation for the&#xD;
             Accreditation of Cellular Therapy) and the criteria specified in FDA 21 Code of&#xD;
             Federal Regulations (CFR) 1271. Specifically, screening for risk factors for&#xD;
             communicable disease as well as infectious disease screening by serologic and PCR&#xD;
             testing as outlined below. Including testing for IV, Hepatitis B, Hepatitis C, HTLV I&#xD;
             and II, CMV, EBV, and toxoplasmosis, westnile virus, syphilis, varicella zoster, and&#xD;
             Chagas disease.&#xD;
&#xD;
          -  Donors must be typed for HLA-A, B, C, DR and DQ at high resolution.&#xD;
&#xD;
          -  Donors accrued at MSKCC must have a hemoglobin value &gt; 10g/dl&#xD;
&#xD;
          -  Donors must be capable of undergoing, at least, a single standard 2 blood volume&#xD;
             leukapheresis or a donation of one unit of whole blood&#xD;
&#xD;
          -  Donors must weight &gt;/= 25 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HTLV/HIV (+) or Hepatitis B or C positive donors&#xD;
&#xD;
          -  Donors who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Prockop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 11, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transplant donor</keyword>
  <keyword>HLA typed</keyword>
  <keyword>17-211</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

